Rhythm Pharmaceuticals wins first-ever approval for acquired hypothalamic obesity; FDA approves Lilly's convenient oral GLP-1 Foundayo as obesity pipeline accelerates
April 1st, 2026: FDA approves Eli Lilly's Foundayo, first convenient GLP-1 pill for weight lossNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Why it matters
Rare and common obesity patients gain new targeted treatments, transforming management from lifestyle-only to effective pharmacotherapy.
White measuring tape with a white pills, white vitamin on a yellow background. Diet. Slimming. Obesity. Place for an inscription. Weight loss marathon. Advertising. Top view. The close plan.
Pink pills arranged in a prohibition symbol in sunlight, symbolizing drug restrictions.
Young South African woman taking insulin for Type 1 diabetes with an insulin injection pen.
How FDA Approved Medications Are Changing Obesity ...
MD Newsline
FDA approves weight loss drug Zepbound, joining Ozempic ...
CBS News
FDA approves diabetes drug to treat obesity
ABC News
Images from Openverse under Creative Commons licenses. Videos from YouTube.
Exploring all sides of a story is often best achieved with Play.
Fictional AI pastiche — not real quote.
"How singular that we have at last found a pill to convince the brain it is satisfied — a sensation the rest of us have been chasing in gin and bad marriages for centuries."
Sign up to generate historical perspectives on this story.
Two rounds, two personas, one winner. You set the crossfire.
Watch two AI personas debate this story using real evidence
Choose one persona for each side of the debate
Select debater for this side:
Select debater for this side:
Make your prediction before the referee scores
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
A Boston-based rare disease company focused on obesity caused by dysfunction in the melanocortin-4 receptor (MC4R) signaling pathway.
The federal agency responsible for evaluating and approving pharmaceutical drugs for safety and efficacy in the United States.
A global pharmaceutical leader advancing oral formulations of incretin therapies for obesity and diabetes.
Danish company dominating obesity treatment with semaglutide-based therapies.
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for obesity that can be taken anytime without food or water restrictions. Phase 3 trials showed 12.4% average weight loss over 72 weeks. Priced at $149/month self-pay, shipping starts April 6.
Rhythm Pharmaceuticals receives FDA approval for the first and only treatment for acquired hypothalamic obesity in adults and children aged 4 and older. The approval was based on the 142-patient TRANSCEND trial showing an 18.4% placebo-adjusted BMI reduction.
The FDA approves Wegovy 7.2 mg, a higher-dose version of the semaglutide injection, achieving 20.7% weight loss—underscoring the rapid expansion of obesity treatment options.
FDA approves oral semaglutide 25 mg (oral Wegovy), eliminating the need for injections. Novo Nordisk prices it at $149 per month.
The FDA accepts Rhythm's supplemental new drug application for review, initially setting a decision deadline of December 2025.
Rhythm Pharmaceuticals announces that setmelanotide achieved a 19.8% placebo-adjusted BMI reduction in 120 patients with acquired hypothalamic obesity over 52 weeks.
Based on the SELECT trial showing a 20% reduction in major cardiovascular events, Wegovy becomes the first drug approved specifically to reduce heart risk in overweight and obese patients.
FDA approves tirzepatide injection, a dual GIP/GLP-1 receptor agonist, for chronic weight management. At its highest dose, patients lost an average of 48 pounds.
FDA approves Imcivree for Bardet-Biedl syndrome, a rare genetic condition affecting an estimated 1,500 to 2,500 Americans. First approved treatment for the condition.
FDA approves semaglutide 2.4 mg injection for chronic weight management, achieving roughly 15% weight loss—approaching surgical results with a weekly injection.
FDA approves setmelanotide for obesity caused by POMC, PCSK1, or LEPR gene deficiencies—conditions affecting only hundreds of patients worldwide.
Belviq (lorcaserin) becomes the first new obesity drug approved since 1999, followed weeks later by Qsymia. Belviq would later be withdrawn in 2020 due to cancer signal.
Fenfluramine pulled from market after causing valvular heart disease. Manufacturer eventually paid over $13 billion in damages. Begins a 13-year freeze on new obesity drug approvals.
Discussed by: Morgan Stanley, Citigroup, and Needham analysts maintaining Buy ratings on Rhythm Pharmaceuticals
With no competing approved treatments and strong clinical data, Imcivree achieves rapid adoption among endocrinologists treating acquired hypothalamic obesity. The roughly 10,000-patient US population, combined with existing rare genetic indications, pushes Rhythm's annual revenue past $400 million within two years. Insurance coverage for rare/acquired conditions proves easier to secure than for common obesity drugs, supporting uptake. Rhythm's pipeline drugs (bivamelagon, RM-718) advance to replace setmelanotide with more convenient or effective next-generation options.
Discussed by: Researchers publishing observational data on semaglutide in hypothalamic obesity, showing 13.4 kg weight loss at 12 months
As GLP-1 drugs like semaglutide and tirzepatide become ubiquitous, some clinicians prescribe them off-label for hypothalamic obesity patients instead of Imcivree, particularly given their broader availability and growing insurance coverage. While setmelanotide targets the specific disrupted pathway, GLP-1 drugs work through partially independent central pathways and are already familiar to prescribers. Imcivree retains an advantage for patients who don't respond to GLP-1 therapy, but the addressable market proves smaller than Rhythm projected.
Discussed by: Nature Reviews and major obesity research conferences tracking 157+ clinical-stage assets across 60+ mechanisms
The parallel expansion of rare-pathway drugs (MC4R agonists) and mainstream drugs (GLP-1, dual and triple agonists, amylin analogues) converges into combination approaches. Clinicians begin combining Imcivree with GLP-1 drugs for hypothalamic obesity patients, similar to how HIV treatment evolved from single agents to multi-drug regimens. Regulatory frameworks adapt to accommodate combination studies across different obesity subtypes, and personalized treatment based on obesity etiology becomes standard practice.
Discussed by: Analysts who cut Rhythm price targets in March 2026 following the EMANATE trial miss
Rhythm's separate EMANATE trial—which tested Imcivree in four additional rare genetic obesities—failed to show statistically significant results, with BMI reductions of only 1.7% to 4.3%. This signals that MC4R agonism has a ceiling and works best only when the melanocortin pathway is specifically and significantly disrupted. Rhythm's expansion opportunities narrow, and the company becomes a niche rare disease firm rather than a platform obesity company. Next-generation pipeline drugs face heightened scrutiny.
Fenfluramine, half of the wildly popular fen-phen diet drug combination that generated 18 million monthly prescriptions in 1996, was pulled from the market after causing heart valve damage. Manufacturer American Home Products (later Wyeth) paid over $13 billion in legal damages. Surveys later found 31% of healthcare providers said they would never prescribe obesity medication again.
The FDA approved no new obesity drugs for 13 years, from 1999 to 2012. Obesity was treated almost exclusively through lifestyle counseling and bariatric surgery.
The scandal created deep regulatory caution and physician reluctance around obesity pharmacotherapy that took two decades and the GLP-1 revolution to overcome.
The fen-phen disaster explains why obesity treatment languished for so long—and why each new approval, especially for vulnerable populations like children with hypothalamic damage, carries heightened scrutiny for safety. Imcivree's clean safety profile in the TRANSCEND trial matters against this backdrop.
The FDA approved Ceredase (alglucerase) for Gaucher disease, an ultra-rare genetic condition affecting roughly 6,000 Americans. Developed by Genzyme, it was one of the first successful rare disease therapies and established the model of orphan drug development—targeting small patient populations with high unmet need at premium prices.
Genzyme built a profitable rare disease business around a single enzyme replacement product, demonstrating that rare conditions could sustain pharmaceutical companies.
The orphan drug model became a standard pharmaceutical strategy: prove efficacy in a rare, well-defined population, then expand to adjacent conditions sharing the same biological pathway.
Rhythm Pharmaceuticals is following the same playbook Genzyme pioneered: start with ultra-rare genetic deficiencies (POMC, PCSK1, LEPR), expand to a broader rare syndrome (Bardet-Biedl), then move into a larger acquired condition (hypothalamic obesity) that shares the same MC4R pathway disruption. The question is how far the pathway-based expansion can reach.
The FDA approved imatinib, a targeted therapy that specifically blocked the BCR-ABL protein driving chronic myeloid leukemia (CML). Developed by Novartis, it transformed CML from a near-certain death sentence into a manageable chronic condition, achieving complete remission in most patients. It was approved in just 2.5 months—one of the fastest reviews in FDA history.
Five-year survival rates for CML jumped from roughly 30% to over 90%. Imatinib became one of the best-selling cancer drugs in history.
Imatinib proved that drugs targeting a specific molecular mechanism could be transformative, launching the era of precision medicine in oncology.
Like imatinib targeting BCR-ABL in leukemia, setmelanotide targets a specific disrupted signaling pathway (MC4R) rather than treating symptoms broadly. Both drugs work best when the underlying biological defect is well understood and directly addressable—and both demonstrate that targeting the right mechanism can produce results in conditions previously considered untreatable.